newsA phase 3 trial studying the effects of tolvaptan has…
8 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
A phase 3 trial studying the effects of tolvaptan has found that the drug slowed the rate of decline in kidney function in patients with polycystic kidney disease...